Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.58 |
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.58 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29421423 | 1.00 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL1538304 | 0.99 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| SCHEMBL22898779 | 0.88 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL29606142 | 0.88 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL24233531 | 0.88 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL22898723 | 0.87 | TLR7 (0.48) | TLR7TLR8NUDT1 | |
| SCHEMBL25575011 | 0.87 | TLR7 (0.46) | TLR7TLR8NUDT1 | |
| Formic Acid SCHEMBL27211547 | 0.84 | TLR7 (0.43) | TLR7TLR8NUDT1 | |
| SCHEMBL7008452 | 0.83 | TLR7 (0.58) | TLR7TLR8NUDT1 | |
| SCHEMBL24024902 | 0.82 | TLR7 (0.43) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | claimed |
| WO-2020252015-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | claimed |
| EP-1455700-A4 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES CO (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1455700-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M Innovative Properties Company (US) | 2004-09-15 | — | — | EP | claimed |
| US-20040014779-A1 | Methods and compositions related to IRM compounds and toll-like recptor pathways | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-22 | — | — | US | claimed |
| WO-2003043572-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-05-30 | — | — | WO | claimed |
| US-20250186581-A1 | SOLANESOL VACCINE ADJUVANTS AND METHODS OF PREPARING SAME | ACCESS TO ADVANCED HEALTH INSTITUTE | 2025-06-12 | — | — | US | disclosed |
| US-12285483-B2 | Solanesol vaccine adjuvants and methods of preparing same | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-04-29 | — | — | US | disclosed |
| EP-2068918-B2 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT | ACCESS TO ADVANCED HEALTH INST (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240139285-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240050561-A1 | SOLANESOL VACCINE ADJUVANTS AND METHODS OF PREPARING SAME | ACCESS TO ADVANCED HEALTH INSTITUTE | 2024-02-15 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| US-11801223-B2 | Single vial vaccine formulations | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2023-10-31 | — | — | US | disclosed |
| US-20050245564-A1 | Methods and compositions related to IRM compounds and toll-like receptor pathways | 3M INNOVATIVE PROPERTIES COMPANY | 2005-11-03 | — | — | US | disclosed |
| WO-2005027841-A2 | CELLS, COMPOSITIONS AND METHODS FOR REPRESSING B CELL AUTOANTIBODY SECRETION AND FOR TREATING AUTOIMMUNE DISEASE | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005023190-A2 | TREATMENT FOR CD5+ B CELL LYMPHOMA | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054665-A1 | Treatment for CD5+ B cell lymphoma | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| EP-1455700-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M Innovative Properties Company (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040014779-A1 | Methods and compositions related to IRM compounds and toll-like recptor pathways | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-22 | — | — | US | disclosed |
| WO-2003043572-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050561-A1 | SOLANESOL VACCINE ADJUVANTS AND METHODS OF PREPARING SAME | SQLE, FDFT1, SGMS1 | TLR7 145/4885TLR8 68/4885NUDT1 4708/4885 |
| US-20240139285-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | TLR7 212/4885TLR8 80/4885NUDT1 2523/4885 |
| US-12285483-B2 | Solanesol vaccine adjuvants and methods of preparing same | SQLE, FDFT1, SGMS1 | TLR7 145/4885TLR8 68/4885NUDT1 4708/4885 |
| US-11801223-B2 | Single vial vaccine formulations | SQLE, ICOS, IL17A | TLR7 60/4885TLR8 691/4885NUDT1 3788/4885 |
| US-20250186581-A1 | SOLANESOL VACCINE ADJUVANTS AND METHODS OF PREPARING SAME | SQLE, FDFT1, SGMS1 | TLR7 145/4885TLR8 68/4885NUDT1 4708/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | TLR7 210/4885TLR8 87/4885NUDT1 2396/4885 |
| US-20040014779-A1 | Methods and compositions related to IRM compounds and toll-like recptor pathways | TLR4, TLR3, TLR6 | TLR7 8/4885TLR8 7/4885NUDT1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.